Keywords: united, therapeutics, plunges, oral, pah, drug, misses

United Therapeutics plunges 33% as oral PAH drug misses Ph III endpoint, filing delay likely

Article | 24 November 2008

Print This

US drugmaker United Therapeutics says that a late-stage pulmonary arterial hypertension trial of oral treprostinil failed to meet its primary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in